NDATOPICALCREAM3 Generics Approved
Approved
Feb 2005
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
3
Data completeness
5/8 — Partial
VANOS (fluocinonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2005.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANOS (fluocinonide) is a potent topical corticosteroid cream approved in 2005 for inflammatory skin conditions. It works by binding to corticosteroid hormone receptors to reduce inflammation, itching, and vasodilation in dermatological indications. Fluocinonide is a synthetic corticosteroid delivered via topical application.
$0.026MPart D
LOE ApproachingDeclining
VANOS faces LOE pressure with minimal Part D spending ($26K in 2023), signaling a small, contracting team with limited growth opportunities in a mature product category.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Fusion The IVANOS-study
Started Mar 2012
102 enrolled
Spinal StenosisLow Back Pain
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
Started Sep 2011
34 enrolled
Breast Carcinoma
VANOS Cream and Skin Barrier Function
Started Jan 2009
25 enrolled
Atopic Dermatitis
Career Relevance
VANOS offers minimal career growth potential given its LOE approaching status and negligible Part D spending ($26K in 2023). Roles on this product are typically maintenance-focused, emphasizing managed decline and generic conversion rather than innovation or expansion.
Worked on VANOS at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.